Regulation & Policy

Draghi on the single market

Country
Italy

Mario Draghi, former president of the European Central Bank, has issued another appeal to policymakers to build an integrated capital market for the EU. In a commentary in the Financial Times on 2-3 November, Mr Draghi argues that a unified market would mobilise private capital to back projects in defence, the building of a digital infrastructure, and the mitigation of climate change. Currently the EU is home to more than 30 national and regional stock exchanges, each with its own regulations. A similar decentralised structure exists for bond markets.

New drug for schizophrenia

Country
United States

A new oral medicine for schizophrenia was approved by the US Food and Drug Administration on 27 September introducing a mechanism of action for treating the disease – a leading cause of disability worldwide. The drug, Cobenfy (xanomeline and trospium chloride), is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which is currently the standard of care. The drug was developed by Bristol-Myers Squibb Co.

FDA approves Itovebi

Country
United States

Itovebi (inavolisib), a kinase inhibitor for use in combination with two other drugs to treat breast cancer, has been approved by the US Food and Drug Administration. This follows a priority review and breakthrough therapy designation for the combination with the marketed breast cancer drugs palbociclib (Ibrance) and fulvestrant (Faslodex). Itovebi targets the PI3K enzyme, a product of the PIK3CA gene. According to the US National Cancer Institute, mutations in the PIK3CA gene have been identified in multiple cancers including breast, lung, ovary, stomach and brain.

Rare disease drug gets approval

Country
United Kingdom

AstraZeneca Plc has received US approval for a new indication for Fasenra (benralizumab), an antibody therapeutic originally developed for asthma and now authorised to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare disease caused by inflammation of small to medium-sized blood vessels. Fasenra binds to a subunit of the interleukin-5 receptor which is predominantly expressed on human eosinophils, a type of white blood cell. Although affecting only an estimated 118,000 people globally, the disease can be fatal without treatment. 

Kisqali wins third cancer indication

Country
Switzerland

The breast cancer treatment Kisqali (ribociclib), first approved in the US in 2017, has received a new indication from the Food and Drug Administration for patients with early cancer who are at a high risk of disease recurrence. The approval, announced by Novartis on 17 September, is based on data from a Phase 3 trial which showed a clinically meaningful reduction in the risk of disease recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative, including those with node-negative disease.

FDA authorises updated Covid-19 vaccines

Country
United States

Covid-19 vaccines manufactured by Moderna Inc and Pfizer Inc have been updated and approved by the US Food and Drug Administration to include a component targeting a new strain of the SARS-CoV-2 virus. The update is the latest move by health authorities to better protect the population against variants of the virus which could lead to hospitalisation or even death.

New indication for Jemperli

Country
United States

GSK Plc has received a new indication from the US Food and Drug Administration for its endometrial cancer medicine Jemperli (dostarlimab) that significantly increases the scope of its coverage. Jemperli is a checkpoint inhibitor that has already been approved for three endometrial cancer indications and for the treatment of patients with mismatch repair-deficient advanced solid tumours. Mismatch repair is a process that corrects errors during the replication of DNA. When this process fails, it can cause cancer.

FDA approves Fabhalta

Country
United States

A new product designed to reduce proteinuria, a feature of a rare disease potentially affecting kidney function, has been given an accelerated approval by the US Food and Drug Administration. The product, Fabhalta (iptacopan), is a small molecule developed by Novartis and the first of several assets from its portfolio of drugs for rare kidney diseases. The FDA approval was announced on 8 August and is based on interim data from a Phase 3 trial investigating Fabhalta in comparison with placebo in patients with primary immunoglobulin A nephropathy (IgAN).

Accelerated approval for cell therapy

Country
United States

The US Food and Drug Administration has given an accelerated approval to a new therapy for synovial sarcoma, the first engineered cell therapy for a solid tumour to receive a marketing approval. The product, Tecelra (afamitresgene autoleucel), is directed against tumours that express the melanoma-associated antigen A4 (MAGE-A4), a marker for the disease. Synovial sarcoma is a rare type of soft tissue sarcoma which can occur in many parts of the body but most frequently in the extremities. The product was developed by Adaptimmune Therapeutics Plc.

EMA turns back Leqembi

Country
Netherlands

The European Medicines Agency has issued a negative opinion for Leqembi (lecanemab), a treatment for Alzheimer’s disease, saying that the benefits of the drug do not outweigh the risks. The opinion, issued on 25 July, is in contrast to decisions by regulatory authorities in six other countries, including the US, which have all approved the treatment. Leqembi is currently being marketed in the US, Japan and China. Co-developer Eisai Co Ltd said that it will appeal against the decision.